(MENAFN) It is buying U.S. drug developer Alexion in a deal value USD39 billion, declared Pharmaceutical company AstraZeneca.
Cambridge, England-based AstraZeneca PLC, which is concerned in one of the efforts to improve a COVID-19 vaccine, stated on Dec. 12 it"s using a mixture of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.
The boards of the two companies generally accepted the transaction, which still needs narrow and shareholder endorsement. The deal is supposed to close in the third quarter of the next year.
AstraZeneca CEO Pascal Soriot declared that, "This acquisition allows us to enhance our presence in immunology."
MENAFN13122020000045011369ID1101272883
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.